ArticleJournal of clinical immunology2026
Porto-sinusoidal Vascular Disease is Associated with Gastrointestinal Disorders in Common Variable Immunodefiency.
Article in Journal of clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Higher serum sCD14 is an independent biomarker for porto-sinusoidal vascular disease risk in CVID.Journal of human immunity · 2027Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to describe porto-sinusoidal vascular disease (PSVD) in a large cohort of predominantly antibody deficiency (PAD) patients and sought to identify contributing factors for PSVD development by comparing CVID patients with and without PSVD.
methodPatients were retrospectively identified from a national database.
resultsSixty-eight of 386 PAD patients, including 63 of 267 CVID patients were diagnosed with PSVD. Median time from PAD to PSVD diagnosis was 9.2 years (interquartile range, 4.6–14.5). CVID patients with late onset combined immunodeficiency and non-infectious complications were overrepresented among PSVD patients (37.5% and 87.3%, respectively). Nodular regenerative hyperplasia (NRH) was the most common finding on liver biopsy (79%), alongside with intra-sinusoidal CD8+ T-cell infiltration (65.7%). In an adjusted multivariate model, gastro-intestinal (GI) complications (adjusted odds ratio, 4.94; 95% CI, 1.91–12.79; p = 0.001) and low naive CD4+ T-cell count (p = 0.001) were strongly associated with the occurrence of PSVD in CVID patients, together with low serum IgA level (p = 0.018) and lymphoproliferation (p = 0.027). GI complications were observed in 90.5% of PSVD patients, preceding PSVD diagnosis in 84% of them by a median duration of 10.7 years. The 20-year probability to develop PSVD after CVID diagnosis was estimated at 38.7% (95% CI, 30.1–48.7) and 11.7% (95% CI, 5.0–26.0) in patients with or without GI complications, respectively (p < 0.001). The median overall survival from onset of PSVD was 8.4 years.
conclusionOur data suggest that impaired intestinal barrier in a context of T-cell defect may play a key role in the development of PSVD in CVID patients. Whether complete control of GI complications would prevent the occurrence of PSVD remains to be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.